Hypoglycemic Drugs
PreclinicalSmall molecule
Hypoglycemic Drugs is one of 47 small molecule programs targeting Metabolic Syndrome. It is currently in Preclinical.
1
Indications
2
Total Trials
1
Active Trials
46
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
70 competitors in Metabolic Syndrome
#DrugCompanyPhaseTrials
1Crestor
AstraZenecaApproved
Actos
TakedaApproved
Cosentyx
NovartisApproved
Avandia
Jazz PharmaceuticalsApproved
Bayer Aspirin
BayerApproved
Uloric
TakedaApproved
Victoza
Novo NordiskApproved
Geodon
PfizerApproved
Ozempic
Novo NordiskApproved
Niacor
AbbVieApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Hypoglycemic Drugs. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details